More information:
Kohei Shitara et al, Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial, The Lancet (2023). DOI: 10.1016/S0140-6736(23)00620-7
https://healthmedicinet.com/i/prolonging-the-survival-of-patients-with-gastric-cancer/